Beludavimab  (Synonyms: BMS 4182137; VIR 7832)

Beludavimab (BMS 4182137; VIR 7832) is a monoclonal antibody targeting the spike glycoprotein of SARS-CoV-2. Beludavimab binds to recombinant spike protein receptor-binding domain (S-RBD) with an EC₅₀ value of 14.9 ng/mL and a K_d of 0.21 nM^[1].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

Beludavimab (VIR 7832) targets an epitope containing a glycan (at position N343) that is highly conserved within the Sarbecovirus subgenus in a region of the S receptor binding domain (RBD) that does not compete with angiotensin converting enzyme 2 (ACE2) binding. Beludavimab possesses an Fc “LS” mutation that confers extended half-life by binding to the neonatal Fc receptor^[1].
Beludavimab induces NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC) in cells from donors expressing the low-affinity F/F158 allele of FcγIIIa more efficiently. Beludavimab neutralizes wild-type and variant pseudotyped viruses and authentic virus in vitro^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

2423016-74-2

[Beludavimab]

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• [1]. Andrea L. Cathcart, et al. The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2. bioRxiv. April 01, 2022.